Acorda Therapeutics, Inc.
ACOR · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Revenue | $117,633 | $118,566 | $129,071 | $152,967 |
| % Growth | -0.8% | -8.1% | -15.6% | – |
| Cost of Goods Sold | $46,047 | $30,332 | $40,787 | $33,513 |
| Gross Profit | $71,586 | $88,234 | $88,284 | $119,454 |
| % Margin | 60.9% | 74.4% | 68.4% | 78.1% |
| R&D Expenses | $5,152 | $5,804 | $10,420 | $23,012 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $89,698 | $106,256 | $124,399 | $152,576 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $51 | $18,210 | $30,764 | $30,763 |
| Operating Expenses | $94,850 | $130,270 | $165,583 | $206,351 |
| Operating Income | -$23,264 | -$42,036 | -$77,299 | -$86,897 |
| % Margin | -19.8% | -35.5% | -59.9% | -56.8% |
| Other Income/Exp. Net | -$272,757 | $6,538 | -$15,154 | -$1,455 |
| Pre-Tax Income | -$296,021 | -$35,247 | -$109,074 | -$107,667 |
| Tax Expense | -$43,167 | $30,669 | -$5,120 | -$8,073 |
| Net Income | -$252,854 | -$65,916 | -$103,954 | -$99,594 |
| % Margin | -215% | -55.6% | -80.5% | -65.1% |
| EPS | -203.59 | -66.9 | -195.75 | -246.4 |
| % Growth | -204.3% | 65.8% | 20.6% | – |
| EPS Diluted | -203.59 | -66.9 | -195.75 | -246.4 |
| Weighted Avg Shares Out | 1,242 | 985 | 531 | 404 |
| Weighted Avg Shares Out Dil | 1,242 | 985 | 531 | 404 |
| Supplemental Information | – | – | – | – |
| Interest Income | $530 | $1,909 | $5 | $816 |
| Interest Expense | $31,533 | $28,291 | $30,035 | $30,574 |
| Depreciation & Amortization | $31,666 | $32,006 | $32,503 | $21,942 |
| EBITDA | -$201,819 | -$10,030 | -$44,796 | -$64,955 |
| % Margin | -171.6% | -8.5% | -34.7% | -42.5% |